P-157 - Mitomycin C, 5-Fluorouracyl and Doxorubicin combination as a second-line chemotherapy in unresectable and metastatic biliary tract carcinoma: result...

Date 04 July 2015
Event WorldGI 2015
Session Posters
Topics Anti-Cancer Agents & Biologic Therapy
Hepatobiliary Cancers
Presenter A. Kuchar
Citation Annals of Oncology (2015) 26 (suppl_4): 1-100. 10.1093/annonc/mdv233
Authors A. Kuchar, R. Stec, L. Bodnar, K. Ostaszewski, J. Korniluk, C. Szczylik
  • Military Institute of Medicine, Warsaw/PL



Biliary tract cancer (BTC) is not very common but has a very poor prognosis. Gemcitabine and platinum combination chemotherapy is the standard treatment for patients with unresectable or metastatic cancer in first-line chemotherapy. There is no standard treatment after progression.


A phase II non-randomised, single-arm study was conducted by the two-step model [Eng et al.] 1. We enrolled patients with advanced biliary tract cancer who progressed on first line therapy. Chemotherapy (Conti-FAM) consisted of mitomycin C 8mg/m2 i.v. on D1, doxorubicin 30mg/m2 i.v. on D1 and 5-fluorouracil 800mg/m2 as a continuous intravenous infusion (10 hours) on D1-D5, every 4 weeks. Therapy was administered until progression or unacceptable toxicity. The primary endpoint of the study was the determination of the rate of patients who survived progression-free for at least 6 months. The secondary objective was to examine overall survival (OS), clinical benefit [(CB) = CR + PR + SD], safety and tolerability. A two-stage design was performed with a possible total of 56 patients. If more than one patient who survived progression-free longer than 6 months was seen in the first 11 eligible patients (stage 1), another 45 patients would be enrolled (stage 2). Response evaluation was done by RECIST criteria (version 1.1) and adverse events were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0)

[1] Eng J. Sample size estimation: how many individuals should be studied? Radiology 2003;



From June 2013 till January 2015, 12 patients were enrolled in Military Institute of Medicine. The median age was 61 years (range, 32-72 years). There were no complete or partial responses. 7/12 patients (58%) had stable disease. There were 17% (2/12) patients survived progression free for at least 6 months from the study entry. Based on the sample size attained in the first stage of accrual, at least one patient who survived progression-free for 6 months we open accrual to the second stage.

Median of PFS was 3,2 months (95%CI; 1,6 to 6,7) (Figure 1). The 1-year survival was 76% (Figure 2). Most common adverse events were anemia, thrombocytopenia, transaminase elevated, nausea and fatigue.


Conti-FAM is an effective and good tolerated treatment as a second-line therapy for patients after progression on chemotherapy based on cisplatin and gemcitabine.

Figure: P-157

Figure: P-157